Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study

J Thromb Haemost. 2012 Nov;10(11):2298-304. doi: 10.1111/j.1538-7836.2012.04907.x.

Abstract

Background: Guidelines for perioperative warfarin management in patients with venous thromboembolic disease (VTE) are largely based on expert opinion.

Objectives: To assess the effectiveness and safety of a conservative perioperative anticoagulation strategy in patients with VTE on chronic warfarin therapy. Our center uses a conservative bridging approach for chronic VTE patients consisting of withholding warfarin for 5 days preoperatively, with prophylactic low-molecular-weight heparin (LMWH) post-procedure only if patients are admitted to hospital.

Patients/methods: We performed a single-center retrospective cohort study. During the study period (1997-2011) there were 634 procedures in 416 patients that were reviewed for postoperative outcomes at 30 and 90 days.

Results: Of the 634 procedures, 156 procedures (24.6%) were completed as inpatients. Pre- and post-procedure LMWH bridging was used in 15 (2.4%) and 152 (24.0%) of all procedures, respectively. The 30-day VTE incidence was 0.32% (95% confidence interval [CI] 0.087-1.14), all non-fatal DVTs. The 30-day incidence of major and total bleeding events was 1.26% (95% CI 0.64-2.47) and 3.00% (95% CI 1.93-4.63), respectively. The all-cause mortality rate was 0.32% (95% CI 0.087-1.14) at 30 days; two patients died from arterial thrombosis events.

Conclusions: A randomized controlled trial is needed to provide definitive conclusions but a conservative bridging approach appears promising.

Keywords: anticoagulants; surgery; thrombosis.

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage*
  • Chronic Disease
  • Female
  • Hemorrhage
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Humans
  • Incidence
  • Inpatients
  • Male
  • Middle Aged
  • Perioperative Period
  • Postoperative Period
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / epidemiology
  • Warfarin / administration & dosage*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Warfarin